60750-75-6

Basic information

• Product Name: 4,6-dimethyl[1,2]thiazolo[5,4-b]pyridin-3(2H)-one
• Synonyms: isothiazolo[5,4-b]pyridin-3(2H)-one, 4,6-dimethyl-
• CAS NO: 60750-75-6
• Molecular Formula: C₈H₈N₂OS
• Molecular Weight: 180.2269
• Mol File: 60750-75-6.mol
• Article Data: 7

Chemical Properties

• Density: 1.322g/cm³
• Refractive Index: 1.631
• CAS DataBase Reference: 4,6-dimethyl[1,2]thiazolo[5,4-b]pyridin-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dimethyl[1,2]thiazolo[5,4-b]pyridin-3(2H)-one(60750-75-6)
• EPA Substance Registry System: 4,6-dimethyl[1,2]thiazolo[5,4-b]pyridin-3(2H)-one(60750-75-6)

Safety Data

• Hazardous Substances Data: 60750-75-6(Hazardous Substances Data)

Usage

Description

4,6-dimethyl[1,2]thiazolo[5,4-b]pyridin-3(2H)-one, also known as Zolpidem, is a nonbenzodiazepine hypnotic medication primarily used for the short-term treatment of insomnia. It works by affecting certain chemicals in the brain that may be unbalanced in people with insomnia, helping to improve sleep onset and maintenance.
Used in Pharmaceutical Industry:
4,6-dimethyl[1,2]thiazolo[5,4-b]pyridin-3(2H)-one is used as a sleep aid for the short-term treatment of insomnia. It is effective in improving sleep onset and maintenance, making it a popular choice for individuals struggling with insomnia.
Used in Medical Treatments:
4,6-dimethyl[1,2]thiazolo[5,4-b]pyridin-3(2H)-one is used as a medication to help individuals with insomnia achieve better sleep quality. It is typically taken orally and its effects can be felt within 30 minutes of ingestion.
However, it is important to note that 4,6-dimethyl[1,2]thiazolo[5,4-b]pyridin-3(2H)-one carries the risk of dependence, tolerance, and potential side effects. Therefore, it should be used with caution and according to a doctor's instructions. It is commonly sold under the brand name Ambien and is available in immediate-release and extended-release forms.

Upstream product

• 14237-71-9 2-chloro-4,6-dimethylnicotinonitrile 
• 102818-01-9 4,6-Dimethyl-2-thioxo-1,2-dihydro-pyridine-3-carboxylic acid benzyloxy-amide 
• 123-54-6 acetylacetone 
• 205171-26-2 2H-2-hydroxymethyl-4,6-dimethyl-3-oxo-2,3-dihydroisothiazolo[5,4-b]pyridine 
• 97248-86-7 2-benzylthio-4,6-dimethylnicotinic acid amide 
• 97248-85-6 2-(benzylsulfanyl)-4,6-dimethylpyridine-3-carbonitrile 
• 79927-21-2 4,6-dimethyl-2-mercaptonicotinic acid amide 
• 54585-47-6 4,6-Dimethyl-2-thioxo-1,2-dihydro-pyridine-3-carbonitrile 
• 79927-21-2 4,6-dimethyl-2-mercaptonicotinamide 
• 54585-47-6 3-cyano-4,6-dimethyl-2-mercaptopyridine 

Downstream Products

• 902589-96-2 YMU-1 
• 1449783-75-8 2-[2-(2-phenoxyethoxy)ethyl]-4,6-dimethylisothiazolo[5,4-b]pyridin-3(2H)-one 
• 1449783-88-3 3-[2-(2-phenoxyethoxy)ethoxy]-4,6-dimethylisothiazolo[5,4-b]pyridine 

Relevant articles and documents

Chemical Inhibition of Human Thymidylate Kinase and Structural Insights into the Phosphate Binding Loop and Ligand-Induced Degradation

Targeting thymidylate kinase (TMPK) that catalyzes the phosphotransfer reaction for formation of dTDP from dTMP is a new strategy for anticancer treatment. This study is to understand the inhibitory mechanism of a previously identified human TMPK (hTMPK) inhibitor YMU1 (1a) by molecular docking, isothermal titration calorimetry, and photoaffinity labeling. The molecular dynamics simulation suggests that 1a prefers binding at the catalytic site of hTMPK, whereas the hTMPK inhibitors that bear pyridino[d]isothiazolone or benzo[d]isothiazolone core structure in lieu of the dimethylpyridine-fused isothiazolone moiety in 1a can have access to both the ATP-binding and catalytic sites. The binding sites of hTMPK inhibitors were validated by photoaffinity labeling and mass spectrometric studies. Taking together, 1a and its analogues stabilize the conformation of ligand-induced degradation (LID) region of hTMPK and block the catalytic site or ATP-binding site, thus attenuating the ATP binding-induced closed conformation that is required for phosphorylation of dTMP.

Synthesis and anorectic activity of 2H-4,6-dimethyl-2-[(4-phenylpiperazin-1-yl)methyl]-3-oxo-2,3 -dihydroisothiazolo[5,4-b]pyridine

The synthesis of 2H-4,6-dimethyl-2-[(4-phenylpiperazin-1-yl)methyl]-3-oxo-2,3 -dihydroisothiazolo[5,4-b]pyridine (3) and its biological properties are described. Compound 3 pharmacologically evaluated in vivo by use of behavioral tests showed to have a profile of activity characteristic of stimulation of the central serotoninergic system, mostly 5-HT(2A) receptors (anorectic action: 2 mg/kg ip, 8.5 mg/kg po). However, receptor activity of isothiazolopyridine 3 was not confirmed in vitro using 5-HT(2A) and 5-HT(1A) receptor binding technique. Molecular modeling studies demonstrated that it is difficult to predict bioactive conformation of title molecule 3.

Synthesis and properties of some derivatives of 2H-4,6-dimethylpyrido[3,2-d]isothiazolin-3-one

-